ADMA Biologics specializes in primary immune deficiencies with Asceniv, a high-margin, unique product that outperforms competitors and has significant growth potential in the U.S. market.

It is developing a pneumonia biologic and has an ongoing pediatric clinical study for Asceniv. Asceniv is a cocktail created from super donors whose plasma contains a high level of antibodies ...

ASCENIV, and Nabi-HB, along with a pipeline targeting S. pneumonia infections. Cramer was asked about the company in August 2024 and he noted that the stock is a spec as he commented ...

Asceniv Global market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 The Business Research Company's Asceniv Global Market Report 2025 – Market Size, Trends, And Global ...